|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | BioForm Medical, Inc. (Nasdaq: BFRM), a medical aesthetics company. |
|---|---|
| Transferring Party | Advanced Cosmetic Intervention, Inc., also a medical aesthetics company. |
| Sector | Medical Devices |
| Date | May 1, 2008 |
| Analysis ACI's GFX device creates RF heat lesions in nerve tissue to weaken nerve signal transduction and reduce the appearance of frown lines. The technology may serve as an alternative to neurotoxin. BioForm will conduct clinical studies to support an FDA application to market the GFX device for the treatment of frown lines, and believes that it can offer synergies with its Radiesse dermal filler product. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |